aestheticmedguideAestheticMedGuide
Injectables

Is Ellanse FDA-Approved? PCL Suture Clearance Is Not a Dermal-Filler PMA

Ellanse is a CE-marked PCL biostimulator, not a US PMA filler. Clinic pages that call it FDA-approved mix suture polymer uses with Sculptra HIV lipoatrophy language. A US NLF trial is not approval.

Ran Chen
Ran Chen
30 min read · Published · Evidence-based

When patients research long-lasting facial collagen stimulators, medical spa blogs and international aesthetic clinic websites frequently claim that Ellansé (polycaprolactone microspheres suspended in a carboxymethylcellulose carrier gel) is "FDA approved." Some providers assert that because polycaprolactone (PCL) is cleared for medical sutures or drug-delivery implants, the injectable filler itself enjoys U.S. Food and Drug Administration (FDA) clearance. Other clinic pages state that Ellansé is "FDA approved for the restoration of facial fat loss," while Google search results display official FDA links alongside clinical trial registries showing an ongoing U.S. study comparing Ellansé to Radiesse.

The regulatory reality is definitive: No. Ellansé is not FDA-approved as a dermal filler in the United States.

In the United States, aesthetic injectable dermal fillers are regulated by the FDA Center for Devices and Radiological Health (CDRH) as Class III medical devices under Product Code LMH (Implant, dermal, for aesthetic use). Class III devices carry the highest regulatory hurdle: they require a complete, prospective Premarket Approval (PMA) application demonstrating reasonable assurance of safety and effectiveness. A manufacturer cannot market a Class III injectable filler based on a 510(k) clearance, a suture polymer clearance, a food-ingredient safety listing, or a foreign regulatory mark.

A census of the FDA Premarket Approval database through 10 July 2026—1,046 Class III dermal-implant records under Product Code LMH—finds zero records for Ellansé, Ellanse, AQTIS Medical B.V., Sinclair Pharmaceuticals, or polycaprolactone. Zero filler PMAs match the product. The official FDA-Approved Dermal Fillers materials page (content current as of 9 November 2020) lists only four material classes: hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and polymethylmethacrylate (PMMA) with bovine collagen. Polycaprolactone is absent from that list. The page is a material-class explainer, not a complete 2026 product table; later HA PMAs exist, but PCL still does not.

This guide analyzes the regulatory census, explains why medical suture clearance and GRAS status do not equal filler approval, examines the ongoing U.S. clinical trial (NCT06984835) and its explicit "unapproved device" status, traces why commercial clinic websites copied Sculptra's historical HIV indication onto Ellansé, and outlines the fully approved biostimulators available in the U.S. today.

Direct Summary: Ellansé U.S. Regulatory Status at a Glance

Feature / Question Regulatory & Clinical Fact
Product Name Ellansé (ELLANSÉ). Current EU SKUs are S and M; older L and E versions are no longer available.
Manufacturer & Sponsor AQTIS Medical B.V. (Utrecht, Netherlands), a subsidiary of Sinclair Pharmaceuticals Limited
Formulation Composition 30% smooth, spherical Polycaprolactone (PCL) microspheres (25–50 µm) suspended in a 70% aqueous Carboxymethylcellulose (CMC) carrier gel
U.S. FDA Approval Status NOT FDA-Approved. Zero PMA records in FDA CDRH database under Product Code LMH.
Total LMH Dermal Filler PMAs 1,046 total records (including original orders and supplements); 0 records match Ellansé or PCL.
Official FDA Filler Materials List Lists HA, CaHA, PLLA, and PMMA only. Polycaprolactone is not on the FDA-approved list.
Active U.S. Clinical Trial NCT06984835: Split-face trial of ELLANSÉ-S vs. Radiesse in nasolabial folds (126 subjects, 7 U.S. sites).
Trial Registry Status Classified by ClinicalTrials.gov as: Studies a U.S. FDA-regulated Device Product: Yes; Unapproved/Uncleared Device: Yes. Active, not recruiting.
Foreign Regulatory Status CE Mark received in Europe (2009) for subdermal facial implantation; registered in multiple Asian, Latin American, and Middle Eastern markets.
Mechanism of Action Immediate volume from CMC carrier gel (resorbed over about 2–3 months) followed by Type I neocollagenesis as PCL microspheres bioresorb.
Reversibility Irreversible with Hyaluronidase. Hyaluronidase only breaks down hyaluronic acid. PCL microspheres cannot be enzymatically dissolved.
Approved U.S. Biostimulators Sculptra (PLLA, PMA P030050), Radiesse (CaHA, PMA P050037 / P050052), and Bellafill (PMMA, PMA P020012).

Is Ellansé FDA-approved as a US dermal filler, or only CE-marked in other markets?

To understand why Ellansé cannot be legally marketed or commercially distributed in the United States, one must examine how the FDA CDRH regulates aesthetic soft-tissue implants compared to European notified bodies.

In the European Union, Ellansé obtained a CE Mark in 2009 under medical device directives (now governed under the EU Medical Device Regulation, EU MDR 2017/745). According to manufacturer technical documentation and Sinclair's commercial labeling (ellanse.com), the approved European intended use is:

"Ellansé is an injectable implant indicated for subdermal implantation in the face for lasting correction of wrinkles and facial aging signs."

In Europe and other CE-mark-recognizing jurisdictions, Sinclair currently sells two Ellansé formulations that differ by polycaprolactone chain length. Those durations are manufacturer commercial claims, not a U.S. label:

  • Ellansé-S: stated longevity of about 18 months;
  • Ellansé-M: stated longevity of about 24 months.

Older L (about 3 years) and E (about 4 years) SKUs still appear on clinic pages and in 2017 technique literature. Sinclair’s March 2022 clinician guide states that Ellansé L and E are no longer available. A U.S. quote that treats a four-rung year ladder as a labeled duration table is using foreign marketing, not an FDA IFU.

However, a CE Mark carries zero legal or regulatory reciprocity in the United States. Under the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act), any medical device intended to be placed into facial soft tissue to improve cosmetic appearance is deemed a Class III device. Under 21 U.S. Code § 360e, Class III devices require an approved Premarket Approval application before commercial introduction into interstate commerce.

The FDA Premarket Approval (PMA) Census

A census of the FDA CDRH Premarket Approval database—56,765 PMA records with decision dates through 10 July 2026—confirms the total absence of Ellansé:

FDA Premarket Approval (PMA) Audit:
Total Records Evaluated: 56,765
Product Code LMH (Aesthetic Dermal Implants): 1,046 records
Product Code PKY (Dermal Implants for Hand Augmentation): 2 records
Queries Run: "Ellanse", "ELLANSE", "AQTIS", "Sinclair", "Polycaprolactone"
Matching Dermal Filler PMA Approvals Found: 0

Across all 1,046 product-code LMH records (which track every original approval and manufacturing or clinical supplement for devices like Juvéderm, Restylane, Sculptra, Radiesse, and Bellafill), not a single entry belongs to Ellansé or AQTIS Medical B.V. Sinclair Pharmaceuticals appears zero times as an applicant under LMH.

A naive query for the substring "ellans" in the broader PMA database yields only a single, unrelated record: P920047/S114 (approved April 16, 2019), which covers Boston Scientific's IntellaNav open-irrigated ablation catheter under Product Code LPB. That cardiac catheter is obviously not an aesthetic dermal filler and must never be conflated with Ellansé.

Similarly, a search of the FDA 510(k) Premarket Notification database (175,559 total clearance records) yields zero clearance records for Ellansé as a dermal implant. The sole case-insensitive substring hit for "ellanse" in the 510(k) database is K053333 (cleared May 2, 2006), covering EagleVision GELLANSERTS under Product Code LZU (Plug, punctum, lacrimal, non-biodegradable). Lacrimal punctal plugs for dry eye are not facial fillers.

The FDA Approved Dermal Fillers List

The FDA maintains an educational registry for clinicians and consumers titled FDA-Approved Dermal Fillers. This page outlines the specific material classes authorized for soft-tissue augmentation in the United States:

  1. Hyaluronic Acid (HA): A naturally occurring glycosaminoglycan temporarily volumizing tissue and reversible with hyaluronidase (e.g., Juvéderm, Restylane, Belotero, RHA);
  2. Calcium Hydroxylapatite (CaHA): Biodegradable mineral microspheres in an aqueous carboxymethylcellulose gel carrier (Radiesse);
  3. Poly-L-lactic Acid (PLLA): Biodegradable synthetic polymer microparticles that induce host neocollagenesis over several months (Sculptra);
  4. Polymethylmethacrylate (PMMA): Non-absorbable synthetic polymer microspheres suspended in bovine collagen carrier gel (Bellafill).

Polycaprolactone is completely absent from this list. While newer HA fillers holding approved PMAs have entered the U.S. market since the FDA page's last static review (for example, Evolysse under PMA P240022, discussed in our guide to new dermal fillers), no PCL-based injectable filler has ever been granted a PMA.

Does PCL in sutures, drug-delivery devices, or a GRAS listing make Ellansé an approved filler?

The most common misleading argument presented on aesthetic clinic websites—such as London's LMA Clinic and Malaysia's Clique Clinic—relies on an invalid regulatory leap: because polycaprolactone is an FDA-cleared polymer used in surgical sutures and orthopedic implants, and because its components are "Generally Recognized as Safe" (GRAS), Ellansé is therefore "FDA approved."

This argument fundamentally misrepresents U.S. medical device law and product safety regulation.

Why Suture Clearance Does Not Equal Dermal Filler Approval:
┌───────────────────────────────────────────────┬───────────────────────────────────────────────┐
│ Surgical Suture / Wound Closure (510k)        │ Injectable Aesthetic Dermal Filler (PMA)      │
├───────────────────────────────────────────────┼───────────────────────────────────────────────┤
│ • Regulated as Class II Medical Device        │ • Regulated as Class III Medical Device       │
│ • Cleared via 510(k) premarket notification   │ • Requires full Premarket Approval (PMA)      │
│ • Evaluates tensile strength, knot security,  │ • Evaluates long-term facial bio-integration, │
│   and linear wound healing                    │   late-onset granulomas, and vascular safety  │
│ • Suture strand anchored across dermis/fascia │ • Microspheres injected in bolus              │
│   with distinct surface-to-volume ratio       │   or retrograde threads into facial planes    │
│ • Clearance covers specific surgical closure, │ • Approval is brand-specific and formulation- │
│   NOT off-target cosmetic soft-tissue filling │   specific; cannot be claimed by analogy      │
└───────────────────────────────────────────────┴───────────────────────────────────────────────┘

1. The Material Clearance Fallacy

Under FDA device regulations, the FDA does not approve raw polymers in the abstract. The FDA approves or clears specific finished medical devices for specific intended uses and indications.

Polycaprolactone is indeed a well-established biodegradable polyester. Peer-reviewed Ellansé literature often points to other caprolactone-containing devices—absorbable sutures such as Monocryl (a glycolide and ε-caprolactone copolymer, not Ellansé’s PCL homopolymer microspheres) and historical drug-delivery implants such as Capronor—as evidence that the polymer class has a medical history. Those citations describe other finished devices. They are not an Ellansé dermal-filler PMA.

However, the clearance of a PCL suture under a Class II 510(k) pathway evaluates the material's mechanical tensile strength, flexibility, knot retention, and local tissue absorption over a narrow suture track. That regulatory review does not evaluate what happens when 25–50 µm PCL microspheres are suspended in a gel carrier and injected as a facial dermal implant intended to remain in place over a multi-year bioresorption window.

The FDA's own materials summary on its dermal fillers page explicitly demonstrates this distinction. Describing Poly-L-lactic acid, the FDA notes:

"Poly-L-lactic acid (PLLA) is a biodegradable, synthetic material that has wide uses in absorbable stitches and bone screws... In the face, it is used to treat deep facial wrinkles."

Notice the critical distinction: the FDA notes that while PLLA has a history of use in stitches and screws, its cosmetic facial use required an independent, rigorous Class III Premarket Approval (Sculptra, PMA P030050). The prior existence of PLLA sutures did not allow the PMA applicant to market Sculptra without conducting multi-center clinical trials. The exact same legal standard applies to polycaprolactone: using PCL in sutures does not exempt Ellansé from requiring a dermal filler PMA.

2. The GRAS Fallacy

Clinic websites that market Ellansé often state that both polycaprolactone and carboxymethylcellulose are "FDA GRAS approved."

This claim represents a profound category error. GRAS (Generally Recognized as Safe) is an administrative designation administered by the FDA's Center for Food Safety and Applied Nutrition (CFSAN) under Sections 201(s) and 409 of the FD&C Act. It applies exclusively to food ingredients and food contact substances that have a demonstrated history of common safe use in foods consumed orally prior to 1958 or consensus among scientific experts based on published feeding studies.

Sodium carboxymethylcellulose (CMC) is indeed a common food thickener and additive holding GRAS status (21 CFR § 182.1745) for ingestion. But GRAS status for ingestion has zero legal relevance to sterile, deep subcutaneous injection into facial tissue. Swallowing an inert polysaccharide thickener in a salad dressing is biologically and toxicologically incomparable to injecting it into facial vascular beds.

Claiming that an injectable cosmetic filler is "FDA approved" because its carrier is GRAS or its polymer is in surgical thread is a deceptive sales tactic designed to obscure the lack of a Class III PMA.

Is NCT06984835 a hidden PMA, or an unapproved-device US trial against Radiesse?

A frequent point of confusion for prospective patients searching the ClinicalTrials.gov database is the appearance of a major U.S. clinical trial evaluating Ellansé. Prospective patients who see a U.S. trial often conclude that the product has achieved FDA endorsement.

The trial in question is NCT06984835 (protocol identifier SES001), officially titled "A Prospective, Multi-Center, Randomized, Controlled, Double-Blind, Split-Face Study of the Safety and Effectiveness of ELLANSÉ-S Dermal Filler in the Treatment of Nasolabial Folds."

Trial Architecture: NCT06984835 Fact Sheet
┌───────────────────────────────┬───────────────────────────────────────────────────────────────┐
│ Feature                       │ ClinicalTrials.gov Registry Record                            │
├───────────────────────────────┼───────────────────────────────────────────────────────────────┤
│ Study Sponsor                 │ AQTIS Medical B.V. (Collaborator: Sinclair Pharmaceuticals)   │
│ First Posted Date             │ May 22, 2025                                                  │
│ Last Update Posted            │ July 21, 2026                                                 │
│ Overall Status                │ Active, not recruiting                                        │
│ Actual Study Start Date       │ March 31, 2025                                                │
│ Estimated Primary Completion  │ August 2026                                                   │
│ Estimated Study Completion    │ December 2027                                                 │
│ Enrollment                    │ 126 subjects (Ages 22 and older)                              │
│ Study Design                  │ Randomized, Split-Face, Double-Blind (participant and          │
│                               │ outcomes assessor), Active-Controlled                         │
│ Active Comparator             │ Radiesse (Merz North America; CaHA filler, PMA P050052)       │
│ Primary Outcome Measure       │ Masked live rater Wrinkle Severity Rating Scale (WSRS) change  │
│                               │ at 6 Months (Non-inferiority to Radiesse)                     │
│ Target Diversity              │ Protocol mandates ≥20% Fitzpatrick IV–VI (≥10% IV, 5% V, 5% VI)│
│ FDA Regulatory Markers        │ Studies a U.S. FDA-regulated Device Product: YES              │
│                               │ Studies an Unapproved/Uncleared Device: YES                   │
└───────────────────────────────┴───────────────────────────────────────────────────────────────┘

An Investigational Device Exemption (IDE) Is Not an Approval

Under federal law (21 CFR Part 812), before an unapproved Class III medical device can be injected into human subjects in the United States, the sponsor must submit an Investigational Device Exemption (IDE) to the FDA.

An IDE allows an investigational device to be used in a clinical study to collect the safety and effectiveness data required to support a future PMA application. On ClinicalTrials.gov, the federal database explicitly flags NCT06984835 with two mandatory statutory disclosures:

  • Studies a U.S. FDA-regulated Device Product: Yes
  • Studies an Unapproved/Uncleared Device: Yes

This formal designation confirms that the FDA treats Ellansé as an unapproved investigational device. The existence of an active trial does not permit commercial sales, does not allow off-study administration, and does not guarantee that the product will ever receive a PMA.

Design of the U.S. Pivotal Study

The study architecture provides valuable insight into how Sinclair hopes to position Ellansé in the U.S. marketplace if it ultimately secures regulatory approval:

  1. Split-Face Active Comparator: The trial uses a split-face model: estimated enrollment is 126 adults, each receiving ELLANSÉ-S in one nasolabial fold and Radiesse in the contralateral fold. Radiesse is the FDA-approved CaHA comparator with an NLF indication (PMA P050052, approved December 22, 2006).
  2. Primary Non-Inferiority Endpoint: The primary objective is to prove that ELLANSÉ-S is non-inferior to Radiesse at Month 6 based on blinded, live-rater assessments using the 5-point validated Wrinkle Severity Rating Scale (WSRS).
  3. Touch-Up and Retreatment Rules: At Week 4, an optional touch-up is permitted using the originally randomized material. Later retreatment, if a fold qualifies at 12 or 18 months, is ELLANSÉ-S only in either fold. Month 24 is a minimum follow-up visit, not a retreatment time point. One-sided retreatment is allowed if only one fold qualifies; the contralateral fold is not then retreated later.
  4. Safety and Skin-of-Color Mandates: The protocol explicitly mandates enrollment of at least 20% subjects with Fitzpatrick Skin Types IV, V, and VI. This is critical for evaluating whether PCL microspheres trigger post-inflammatory hyperpigmentation (PIH) or delayed hypertrophic tissue responses in melanin-rich skin.
  5. Timeline to Market: The registry still lists estimated primary completion as August 2026 and estimated study completion as December 2027. As of the 21 July 2026 update, overall status remains Active, not recruiting, and no results are posted. Estimated dates are not posted WSRS n/N and are not a PMA.

Even if a future 6-month WSRS readout shows non-inferiority, that still is not marketing approval. The sponsor would need an approved PMA before Ellansé could be legally sold in the U.S. As of September 2026, that process has not occurred.

Our related guide to nasolabial fold treatments tracks pipeline fold trials, but readers evaluating current clinic options must recognize that NCT06984835 is an investigational research protocol, not commercial availability.

Why do clinic pages copy Sculptra HIV facial-lipoatrophy language onto Ellansé?

One of the most revealing findings in ranking results for "is Ellanse FDA approved" is that multiple commercial clinic websites feature identical, highly specific phrasing describing Ellansé's purported FDA approval.

Consider the claims published on two prominent international clinic portals:

  • LMA Clinic (London): Claims that "Ellansé is officially approved by the MHRA in the UK and the FDA in the USA for restoration and correction of the signs of facial fat loss."
  • Clique Clinic (Malaysia): Claims that "Ellanse is officially approved by the MHRA in the UK and the FDA in the USA for the restoration and/or correction of the signs of facial fat loss (lipoatrophy)."

Where did this exact phrase—"restoration and/or correction of the signs of facial fat loss (lipoatrophy)"—originate?

It was not written for Ellansé. It was lifted verbatim from the FDA's original August 3, 2004 Approval Order for Sculptra (PMA P030050).

The Anatomy of Copied Regulatory Language:
┌───────────────────────────────────────────────────────────────────────────────────────────────┐
│ FDA Approval Order for Sculptra (PMA P030050 ORIG, August 3, 2004):                           │
│ "Sculptra is indicated for restoration and/or correction of the signs of facial fat loss      │
│ (lipoatrophy) in people with human immunodeficiency virus (HIV)."                             │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Copied Clinic Web Copy on Ellansé (LMA Clinic / Clique Clinic):                               │
│ "Ellansé is officially approved by... the FDA in the USA for the restoration and/or           │
│ correction of the signs of facial fat loss (lipoatrophy)."                                    │
└───────────────────────────────────────────────────────────────────────────────────────────────┘

When Dermik Laboratories (and later Galderma) achieved the first U.S. approval for an injectable poly-L-lactic acid biostimulator in 2004, the FDA granted an expedited review specifically for HIV-associated facial lipodystrophy. That landmark clinical indication became a staple of dermatologic literature.

Over the subsequent two decades, secondary marketing agencies drafting web copy for international medical spas conflated poly-L-lactic acid with polycaprolactone, cut and pasted the historical Sculptra indication language onto Ellansé, and told prospective patients that the FDA had approved Ellansé for facial fat loss.

This error is compounded by search engine algorithms. When a user asks Google whether Ellansé is FDA-approved, the search engine indexes the clinic's cut-and-paste text alongside the FDA's generic approved-fillers list. Prospective patients reading snippet summaries are led to believe that Ellansé has a formal lipoatrophy indication in the United States. In truth, P030050 belongs exclusively to Sculptra. Ellansé has zero FDA approvals for facial lipoatrophy, nasolabial folds, or any other medical or aesthetic indication.

For an in-depth review of how Sculptra's original HIV approval evolved into cosmetic facial and off-label body use, see our comprehensive analysis of Sculptra FDA approval for the buttocks and how long Sculptra takes to work.

Which US biostimulators actually have PMAs (Sculptra, Radiesse, Bellafill), and is HArmonyCa the same decision?

Patients inquiring about Ellansé are typically seeking long-lasting neocollagenesis—injectables that stimulate the body's fibroblasts to produce natural structural collagen rather than relying solely on temporary hyaluronic acid gel filler projection.

In the United States, patients do not need to seek unapproved foreign products. The FDA has approved three distinct biostimulatory and semi-permanent filler platforms through rigorous PMA clinical pathways:

FDA-Approved Biostimulator Architecture in the United States:
┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
│ Sculptra (Galderma)           │ Radiesse (Merz Aesthetics)    │ Bellafill (Tiger Aesthetics)  │
├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
│ • PMA P030050 (54 LMH rows)   │ • P050037 HIV (2006-12-22)    │ • PMA P020012 (43 LMH rows)   │
│ • Approved: Aug 3, 2004 (HIV) │ • P050052 NLF (2006-12-22);   │ • Approved: Oct 27, 2006      │
│   Jul 28, 2009 (NLF wrinkles) │   hands S049 2015-06-04 (PKY) │ • 20% PMMA microspheres       │
│   Apr 25, 2023 (cheek lines)  │ • ~30% CaHA microspheres      │   (30–50 µm) in bovine        │
│ • PLLA microparticles with    │   (25–45 µm) in CMC gel       │   collagen carrier            │
│   CMC and mannitol (367.5 mg  │ • Immediate lift from CMC     │ • Permanent synthetic matrix  │
│   dose vial; 40–63 µm)        │   + 12–18 mo CaHA collagen    │ • Mandatory skin allergy test │
└───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘

1. Sculptra (Poly-L-lactic Acid; PMA P030050)

Held by applicant Q-Med AB (Galderma), Sculptra is the preeminent synthetic biostimulator in the U.S. It operates by recruiting subclinical macrophages and fibroblasts to deposit Type I and Type III collagen as the microparticles degrade via non-enzymatic hydrolysis into lactic acid monomers.

Unlike Ellansé, which provides immediate projection from its 70% CMC carrier, Sculptra provides no immediate true volume once the sterile water for injection (SWFI) carrier absorbs over the first 48 to 72 hours. Collagen buildup occurs gradually over three to six months. Sculptra is fully bioabsorbable and FDA-approved for named facial indications (HIV facial lipoatrophy, nasolabial folds and other facial wrinkles, and cheek fine lines). For clinical comparisons against HA and CaHA, see our guides on Sculptra vs. Radiesse and Sculptra vs. Dermal Filler.

2. Radiesse (Calcium Hydroxylapatite; PMA P050037 & P050052)

Held by Merz North America, Radiesse provides a hybrid clinical effect remarkably similar to the mechanism Ellansé pursues:

  • Immediate structural lifting and contouring provided by its aqueous carboxymethylcellulose (CMC) carrier gel;
  • Long-term dermal thickening and elasticity improvement as its 25–45 µm smooth calcium hydroxylapatite microspheres stimulate fibroblasts to form collagen and elastin over 12 to 18 months.

Radiesse holds approved FDA indications for deep facial folds (nasolabial folds under P050052) and hand dorsum rejuvenation (P050052/S049, product code PKY). Hyperdilute neck, décolleté, or body use is a Radiesse labeling question, not an Ellansé approval. For durability and labeled versus off-label dilution, consult how long Radiesse lasts.

3. Bellafill (PMMA with Bovine Collagen; PMA P020012)

Originally approved as Artecoll/Artefill on October 27, 2006, Bellafill represents the only permanent dermal implant approved by the FDA for facial aesthetics (nasolabial folds and distensible atrophic acne scars). It consists of non-resorbable polymethylmethacrylate (PMMA) microspheres suspended in a bovine collagen carrier.

While Ellansé is bioabsorbable on a manufacturer-stated 18- to 24-month window for current S and M SKUs (older L/E year ladders are withdrawn), Bellafill's PMMA beads remain in the tissue permanently, serving as an enduring scaffold for host tissue ingrowth. Because Bellafill contains bovine collagen, it requires a mandatory pre-treatment skin allergy test. For a detailed breakdown of permanent filler risks, see our guide to Bellafill permanent PMMA filler.

Is HArmonyCa the Same Regulatory Decision?

Patients researching international biostimulators frequently group Ellansé with HArmonyCa Lidocaine, Allergan Aesthetics' dual-effect injectable combining cross-linked hyaluronic acid and calcium hydroxylapatite microspheres.

While both products are marketed across Europe and Latin America, neither is FDA-approved in the United States. As documented in our dedicated investigation into HArmonyCa FDA approval status, HArmonyCa also holds zero PMA approvals under Product Code LMH.

However, the regulatory and research landscape differs:

  • HArmonyCa's primary active trial (NCT07032597) is an ex-U.S. Phase 3 study sited exclusively in China comparing HArmonyCa to Restylane Perlane, alongside completed trials in Canada, Spain, and the UK;
  • Ellansé's sponsor, by contrast, is actively conducting a 7-site U.S. trial (NCT06984835) against Radiesse under a U.S. IDE.

Nevertheless, the bottom-line rule for U.S. patients remains identical: both HArmonyCa and Ellansé are unapproved medical devices in the United States. Neither can be legally administered outside an authorized clinical trial protocol.

Who should skip a US Ellansé quote (FDA-approved claim, gray-market syringe, EU duration SKU, wanting hyaluronidase reversal)?

Because Ellansé has achieved widespread popularity on social media and international aesthetic forums, some U.S. consumers encounter domestic medical spas or independent injectors offering "exclusive European Ellansé treatments."

Administering or receiving Ellansé in a commercial U.S. medical setting outside an FDA-cleared clinical trial involves severe legal, safety, and clinical risks. Prospective patients should recognize the following absolute red flags and skip any clinic offering this product:

Critical Patient Decision Matrix: When to Skip an Ellansé Quote
┌───────────────────────────────────────┬───────────────────────────────────────────────────────┐
│ Red Flag Scenario                     │ Clinical & Safety Reality                             │
├───────────────────────────────────────┼───────────────────────────────────────────────────────┤
│ 1. Clinic Claims "FDA-Approved"       │ Immediate disqualifier. The provider is either        │
│                                       │ misinformed or deliberately deceptive about the       │
│                                       │ regulatory status of the device.                      │
├───────────────────────────────────────┼───────────────────────────────────────────────────────┤
│ 2. Syringe Sourced via "Gray Market"  │ Sourced via unregulated international gray-market     │
│                                       │ exporters. Zero verified cold-chain shipping, high    │
│                                       │ risk of counterfeit or adulterated batches.           │
├───────────────────────────────────────┼───────────────────────────────────────────────────────┤
│ 3. Offered EU Duration SKUs in the US │ Quoting "Ellansé-M (2-year)" or withdrawn "Ellansé-E  │
│                                       │ (4-year)" uses foreign commercial SKUs that have zero │
│                                       │ recognized standing as a U.S. duration table.         │
├───────────────────────────────────────┼───────────────────────────────────────────────────────┤
│ 4. Expectation of Reversibility       │ PCL microspheres CANNOT be dissolved with             │
│                                       │ hyaluronidase. If a nodule, asymmetry, or vascular    │
│                                       │ occlusion occurs, reversal is extraordinarily complex.│
├───────────────────────────────────────┼───────────────────────────────────────────────────────┤
│ 5. Seeking Off-Label Body Contouring  │ Using imported PCL for non-surgical buttock, breast,  │
│                                       │ or hip augmentation multiplies inflammatory surface   │
│                                       │ area with zero FDA safety oversight.                  │
└───────────────────────────────────────┴───────────────────────────────────────────────────────┘

1. The Provider Claims Ellansé Is FDA-Approved

If a practitioner tells you that Ellansé is FDA-approved, that PCL suture clearance covers the product, or that a U.S. clinical trial means it is authorized for general use, decline the treatment immediately. A medical provider who does not know the regulatory status of the substances they inject cannot be trusted to manage complex complications, understand adverse event reporting, or adhere to federal safety standards.

2. Gray-Market Syringes and Supply-Chain Contamination

Because Sinclair Pharmaceuticals cannot legally distribute Ellansé through authorized commercial channels in the United States, any syringe present in a domestic medical spa has been imported through illicit, gray-market secondary distributors (often shipped via parcel freight from overseas pharmacies).

As detailed in our analysis of unapproved skin boosters and imported injectables, gray-market aesthetic products bypass FDA border inspection and U.S. Customs and Border Protection (CBP) surveillance. These syringes have no verifiable chain of custody:

  • They may have been subjected to extreme temperature fluctuations during transit, compromising the suspension rheology and viscosity of the CMC carrier gel;
  • They carry a high risk of being counterfeit, containing sub-potent, unsterilized, or particulate-contaminated formulations;
  • In the event of an adverse clinical outcome, malpractice policies may exclude injuries from unapproved imported devices, and the manufacturer cannot provide domestic medical affairs support.

3. Irreversibility and the Hyaluronidase Myth

The most critical clinical risk that prospective patients fail to understand is reversibility.

With standard hyaluronic acid fillers (such as Juvéderm, Restylane, Belotero, or RHA), inadvertent intra-arterial vascular occlusion or superficial misplacement can be treated with hyaluronidase, which hydrolyzes hyaluronic acid. For enzymatic dissolution mechanics, consult our guide to dissolving filler with hyaluronidase.

Polycaprolactone microspheres cannot be dissolved with hyaluronidase. Hyaluronidase has no enzymatic activity against PCL polyesters or carboxymethylcellulose. If Ellansé enters a vessel, hyaluronidase cannot clear a mechanical microsphere occlusion. Vascular occlusion, skin necrosis, and vision loss are named risks of soft-tissue fillers; they are not managed with an HA-dissolving enzyme. For that emergency class, see filler vascular occlusion.

If product is misplaced or delayed inflammatory nodules appear months later, the microspheres still cannot be dissolved. Management is then a clinician decision, not an enzymatic reversal.

In a 2025 systematic review of filler-induced foreign-body granulomas by Wang and colleagues (biostimulators vs. HA fillers), polycaprolactone accounted for 4% of 117 documented granuloma cases. That figure is a proportion of a tertiary referral case-mix, not a population incidence rate. It still shows that biostimulatory microspheres carry persistent immunologic risks that hyaluronidase does not reverse.

4. What Does Ellansé Cost in the United States?

Because Ellansé has no FDA approval and no legal U.S. distribution, there is no legitimate U.S. manufacturer list price. Any U.S. clinic quoting a dollar fee for Ellansé is selling an unapproved imported device, not a labeled U.S. product. Patients who want a collagen stimulator in the United States should be quoted FDA-approved options such as Radiesse or Sculptra.

Frequently Asked Questions

Is Ellansé FDA-approved in the United States?

No. Ellansé has never received Premarket Approval (PMA) from the U.S. FDA as a dermal filler. A census of all 1,046 Class III aesthetic dermal implant PMA records under Product Code LMH through 10 July 2026 finds zero entries for Ellansé, AQTIS Medical, or polycaprolactone. The official FDA-Approved Dermal Fillers materials list (current as of 9 November 2020) names hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, and PMMA.

Is Ellansé available in the US if a clinic or website will sell it?

Ellansé cannot be legally sold, shipped into interstate commerce, or administered as a commercial dermal filler in the United States. Any U.S. medical spa offering Ellansé has procured the product through unauthorized gray-market international supply chains. Such syringes bypass FDA inspection, lack temperature-controlled custody documentation, and carry severe risks of counterfeiting or contamination.

Does the US ELLANSÉ-S clinical trial mean Ellansé is FDA-approved?

No. The active U.S. study (ClinicalTrials.gov identifier NCT06984835) is an investigational trial conducted under an Investigational Device Exemption (IDE). ClinicalTrials.gov explicitly marks the study as evaluating an "Unapproved/Uncleared Device." An IDE allows clinical investigators to gather safety and effectiveness data in enrolled human subjects; it does not constitute marketing clearance, commercial approval, or an FDA endorsement.

Is Ellansé better than Sculptra or Radiesse in the United States?

In the United States, Sculptra (PMA P030050) and Radiesse (PMA P050052) are fully FDA-approved biostimulators backed by extensive, peer-reviewed clinical trials, published Summaries of Safety and Effectiveness Data (SSED), and domestic manufacturer pharmacovigilance. Because Ellansé has not received FDA approval and its U.S. comparative trial against Radiesse has not published final results, claims that Ellansé is "better" or "longer-lasting" are unvalidated promotional assertions that ignore the legal and safety protections of FDA-approved alternatives.

Can Ellansé be dissolved with hyaluronidase?

No. Hyaluronidase specifically cleaves the beta-1,4 glycosidic bonds in hyaluronic acid. Ellansé is composed of polycaprolactone (PCL) microspheres in a carboxymethylcellulose (CMC) carrier gel; it contains zero hyaluronic acid. Hyaluronidase has no effect on PCL. If misplaced filler, late-onset granulomas, or acute vascular occlusion occurs, the product cannot be dissolved enzymatically.

Why do some clinics say Ellansé is FDA-approved for facial fat loss?

Multiple commercial clinic websites mistakenly copied the exact indication language from Sculptra's original August 3, 2004 FDA Premarket Approval (PMA P030050), which approved poly-L-lactic acid for "restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus." Marketing writers erroneously applied this historical PLLA reconstructive indication to Ellansé's PCL formulation, creating persistent misinformation in search engine results.

What to Ask If a Clinic Quotes Ellansé in the United States

If you consult with an aesthetic medical practice in the United States and the provider recommends or offers Ellansé, protect your health, legal rights, and financial investment by asking these direct, factual questions:

  1. "Can you provide the FDA Premarket Approval (PMA) number for Ellansé?"
    Why to ask: Legitimate U.S. fillers possess clear PMA numbers verifiable on accessdata.fda.gov (e.g., P050052 for Radiesse, P030050 for Sculptra, P110033 for Juvéderm Voluma). The injector will not be able to provide one because none exists.
  2. "Is this office a formally registered site on ClinicalTrials.gov protocol NCT06984835, and will I be signing an IRB-approved investigational consent form?"
    Why to ask: The only lawful setting in which Ellansé may be administered in the U.S. is an authorized clinical research site with institutional review board (IRB) oversight. If the clinic is charging you commercial retail rates for a standard office procedure, they are not operating under the trial protocol.
  3. "Where was this syringe purchased, who was the licensed U.S. distributor, and how was cold-chain temperature tracked from the European factory?"
    Why to ask: Because Sinclair cannot legally distribute Ellansé commercially in the U.S., any syringe in the clinic was acquired through secondary gray-market channels. If the clinic cannot name an authorized domestic distributor, the syringe's sterility and authenticity cannot be confirmed.
  4. "If a complication or vascular occlusion occurs, what is your specific emergency protocol given that PCL cannot be dissolved with hyaluronidase?"
    Why to ask: Ensures the provider recognizes that enzymatic reversal is impossible and reveals whether the practice possesses hospital admitting privileges or established complication management workflows.
  5. "Can we achieve my biostimulatory and collagen-regeneration goals using FDA-approved alternatives like Radiesse or Sculptra?"
    Why to ask: Redirects your treatment plan to well-characterized, legally approved products that offer established safety profiles, predictable degradation timelines, and full domestic clinical support.

For broader guidance on regulatory boundaries, clinician qualifications, and off-label consent standards, explore our reference guides to off-label aesthetic injections and dermal filler complications.

Sources

Topics
Dermal FillersBiostimulatorsSculptraRadiesseBellafillSafetyRegulatoryCost
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Injectables

See all →
Injectables · 27 min read

Is Sculptra FDA-Approved for the Buttocks? Three Face Indications, Zero Gluteal PMA

US Sculptra is PMA P030050 for face only: HIV lipoatrophy, nasolabial folds, and cheek wrinkles. A Sculptra butt lift is off-label. Cleveland Clinic…

Injectables · 27 min read

How Long Does Radiesse Last? Area-by-Area PMA Duration, Not One 12-to-18-Month Number

Radiesse duration is PMA- and area-specific. Manufacturer up-to-2-years is not the SSED table. Décolleté 1:2 is labeled; hyperdilute body is not.

Injectables · 14 min read

Is HArmonyCa FDA Approved? Hybrid HA + CaHA Filler Status in the US

HArmonyCa is a hybrid HA plus CaHA filler with CE Mark and a 2026 Canadian launch. It is not FDA-approved. How to read MAUDE noise, the China Phase 3…